Today's Top Stories


Hot Topics


Comment & Analysis »

GlobalData Healthcare

Competition is heating up in long-acting growth hormones for children

Suboptimal outcome due to poor adherence to daily injection of human growth hormones (hGHs) is universally recognized among physicians as one of the greatest barriers in growth hormone...

Competition is heating up in long-acting growth hormones for children
GlobalData Healthcare

Promising preliminary data from Phase II study encourages Axovant to expand trial

Promising preliminary data from Phase II study encourages Axovant to expand trial
GlobalData Healthcare

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data
GlobalData Healthcare

When faster is not better: the 'surrogate' example

When faster is not better: the 'surrogate' example
Umesh Ellichipuram

January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk

January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk

Company Releases »

ePAT Automated Lab Reactor Optimised for 24/7 Data Capture

SYSTAG Systems Technik
ePAT Automated Lab Reactor Optimised for 24/7 Data Capture

How Investing in Malvern Instruments Helped KBI Biopharma Find a Clear Commercial Advantage

Malvern Instruments
How Investing in Malvern Instruments Helped KBI Biopharma Find a Clear Commercial Advantage

Optimising Development Resources for Efficient Product Development

SYSTAG Systems Technik Optimising Development Resources for Efficient Product Development

GPC/SEC Analysis of Polymer Solutions Used in Inkjet Printing

Malvern Instruments
GPC/SEC Analysis of Polymer Solutions Used in Inkjet Printing

Gold Nanoparticle Applications and Characterization by Nanoparticle Tracking Analysis

Malvern Instruments Gold Nanoparticle Applications and Characterization by Nanoparticle Tracking Analysis

Drugdevelopment Insights »

Drugdevelopment Industry Reports »

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

Report: Growth Expected in Dyslipidemia market to $29bn by 2025

Report: Growth Expected in Dyslipidemia market to $29bn by 2025

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

Report: Partnerships between big pharma and small biotech to dominate Lupus R&D landscape

Report: Partnerships between big pharma and small biotech to dominate Lupus R&D landscape